CRISPR Therapeutics AG
CRSP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $286 | $197 | $235 | $298 |
| Short-Term Investments | $1,629 | $1,528 | $1,620 | $1,606 |
| Receivables | $0 | $0 | $0 | $25 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $13 | $9 | $12 | $8 |
| Total Curr. Assets | $1,929 | $1,734 | $1,868 | $1,937 |
| Property Plant & Equip (Net) | $255 | $263 | $270 | $278 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $28 | $31 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $32 | $3 | $29 | $27 |
| Total NC Assets | $316 | $296 | $298 | $305 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $2,245 | $2,030 | $2,166 | $2,242 |
| Liabilities | – | – | – | – |
| Payables | $12 | $10 | $13 | $15 |
| Short-Term Debt | $18 | $18 | $18 | $17 |
| Tax Payable | $3 | $1 | $1 | $0 |
| Deferred Revenue | $1 | $2 | $3 | $4 |
| Other Curr. Liab. | $84 | $74 | $85 | $51 |
| Total Curr. Liab. | $119 | $104 | $119 | $88 |
| LT Debt | $193 | $197 | $202 | $206 |
| Deferred Rev, NC | $12 | $12 | $12 | $12 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $5 | $4 | $3 | $3 |
| Total NC Liab. | $210 | $214 | $217 | $222 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $193 | $197 | $202 | $206 |
| Total Liabilities | $329 | $319 | $337 | $310 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $3 | $3 | $3 | $3 |
| Retained Earnings | -$1,817 | -$1,710 | -$1,502 | -$1,366 |
| AOCI | $5 | $4 | $4 | $2 |
| Other Equity | $3,725 | $3,415 | $3,324 | $3,293 |
| Total Equity | $1,916 | $1,711 | $1,829 | $1,932 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $2,245 | $2,030 | $2,166 | $2,242 |
| Net Debt | -$75 | $18 | -$16 | -$75 |